Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

New Insights into Hepatitis B Virus Biology and Implications for Novel Antiviral Strategies

Cytokines and Chemokines in HBV Infection

Progress of Infection and Replication Systems of Hepatitis B Virus

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Current trends and advances in antiviral therapy for chronic hepatitis B

HBV life cycle and novel drug targets

Hepatitis B: Model Systems and Therapeutic Approaches

Interplay between hepatitis B virus and the type Ⅰ interferon system and new therapeutic strategies

Hepatitis B: New Approaches for Antiviral Chemotherapy

New advances in drug therapy of chronic hepatitis B infection

Animal Models for the Study of Hepatitis B Virus Pathobiology and Immunity: Past, Present, and Future

Novel Approaches Towards Conquering Hepatitis B Virus Infection

Development of novel therapeutics for chronic hepatitis B

Emerging Antivirals for the Treatment of Hepatitis B

Advances in Research and Development of New Drugs for Antiviral Therapy for Chronic Hepatitis B

Interplay Between Hepatitis B Virus and the Innate Immune Responses:Implications for New Therapeutic Strategies

HBV Genome and Life Cycle

Overview of the Development of HBV Small Molecule Inhibitors

Perspectives in the Development of New Drugs Against Hepatitis B Virus

Advances in drugs and biotechnology targeting hepatitis B virus cccDNA

Recent Advances in Screening Methods Enabling the Discovery of Novel Anti-Hepatitis B Virus Drug Candidates